AccuShares(R) Investment Management, LLC Announces Regular

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AccuShares(R) Investment Management, LLC Announces Regular Distribution for the AccuShares Spot CBOE(R) VIX(R) Up Shares and Down Shares and, If Applicable, Net Income Distribution for the AccuShares Spot CBOE VIX Up Shares and Down Shares

STAMFORD, CT --(Marketwired - May 16, 2016) - AccuShares Investment Management, LLC ("AccuShares"), as sponsor of the AccuShares Trust I (formerly known as Accushares Commodities Trust I) (the "Trust"), today announced the Regular Distribution payment for the Spot CBOE VIX Up Shares ( NASDAQ : VXUP ) and Spot CBOE VIX Down Shares ( NASDAQ : VXDN ), and, if applicable, the Net Income Distribution payment for the AccuShares Spot CBOE VIX Up Shares and Down Shares, as such distributions are described in the current prospectus of the AccuShares Spot CBOE VIX Fund (the "Fund").

The relevant distribution information is provided in the tables below:

Distribution Dates :

                     
NASDAQ Ticker   Name   Ex Date   Record Date   Distribution Payment Date   Regular Distribution Measurement Schedule
VXUP   AccuShares Spot CBOE VIX Up Shares   May 17, 2016   May 19, 2016   May 23, 2016   Monthly
VXDN   AccuShares Spot CBOE VIX Down Shares   May 17, 2016   May 19, 2016   May 23, 2016   Monthly
                     

Distribution Amount Information :

                         
NASDAQ Ticker   Name   Closing Index Value as of May 16, 2016   Post-Distribution Share Index Factor*   Post-Distribution Class Value per Share*   Net Income Distribution Amount   Regular Distribution Amount**
VXUP   AccuShares Spot CBOE VIX Up Shares   14.68   0.37942779   $5.57   $0.000000   $0.395814
VXDN   AccuShares Spot CBOE VIX Down Shares   14.68   -0.37942779   $5.57   $0.000000   $0.000000
                         

* As defined in the Fund's prospectus.

** A portion of the distribution includes a return of capital.

More information about the Fund can be found at the Trust's website at www.accushares.com

Investor Reassessment:

Investors wishing to maximize exposure to the index tracked by the Fund, the CBOE Volatility Index, in either direction or investors wishing to compound gains over one or more distribution dates must invest any cash distributed, and sell any shares distributed and invest the sale proceeds thereof, in the class of shares aligned with their investment objectives.

The Fund has been designed to be utilized by investors who are prepared to reassess their holding of the Fund's shares at least as frequently as each distribution date. Investors in the Fund who wish to maintain a maximum exposure, a targeted absolute exposure, or a targeted relative exposure to the Underlying Index over multiple distribution dates should reassess their positions following all cash and share distributions, and all Fund resets relating to the Share Index Factors. The Fund will not compound investor gains or otherwise rebalance investor positions to maximize investor exposure. The Fund is designed to make Regular Distributions of cash and in some cases shares to facilitate regular distribution of investor gains and to promote a deliberate and regular reassessment by investors of their investment in the Fund.

Investors who hold shares over one or more consecutive distribution dates without reassessment of their Fund share portfolio may experience decreased exposure to the Underlying Index as well as a reduced opportunity for gain and loss.

About AccuShares:

Founded in 2011, AccuShares ( www.accusharesinvmgmt.com ) is an innovative financial services firm sponsoring exchange traded products ("ETPs") that provide access to indices in key alternative asset classes, including volatility. AccuShares ETPs offer investors the ability to trade both shares that are positively linked with the ETP's index ("Up Shares") and shares that are negatively linked with such index ("Down Shares"), enabling them to potentially take advantage of opportunity in any market. AccuShares' patent-pending technology and "direct-to-index" quantitative design seeks to reduce overall expenses while also attempting to both simplify tax reporting and provide investors with a predictable cost of ownership and transparency in returns.

Disclosures:

Neither the Trust nor the Fund is an investment company within the meaning of the Investment Company Act of 1940 and neither is subject to regulation thereunder. Although AccuShares is registered as a commodity pool operator with the Commodity Futures Trading Commission ("CFTC"), the Trust and the Fund are not subject to regulation under the Commodities Exchange Act or by the CFTC. Consequently Fund shareholders are not afforded the regulatory protections provided to investors in registered investment companies or commodity pools.

Investing in the Funds involves substantial risk and high volatility, including possible loss of principal. Shares of the fund are intended for sophisticated, professional and institutional investors. The Fund is not intended to be used as a long-term passive investment vehicle and should be used by investors who understand the risks of the volatility market. Investors expecting the Underlying Index to decline should purchase the Fund's Down Shares, and investors expecting the Underlying Index to increase should purchase the Fund's Up Shares, to align their respective Fund investments with their respective expectations. Please read the Fund's prospectus carefully before investing. The Fund's prospectus can be obtained by clicking the link below.

http://www.accushares.com/resources/vix-fund-prospectus

The Trust is a Delaware statutory trust organized by AccuShares into separate fund series. The Fund's shares represent fractional undivided interests in and ownership of the Fund only and not any other series of the Trust or the Trust as a whole. The Fund offers its shares on a continuous basis and is listed on the NASDAQ.

Disclaimers:

The Fund is not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices LLC (the "Index Provider"), Dow Jones Trademark Holdings LLC ("Dow Jones"), Standard & Poor's Financial Services LLC ("S&P"), their respective affiliates or their third party licensors (including The Chicago Board Options Exchange Incorporated ("CBOE")) and none of such parties make any representation or warranty, express or implied, regarding the advisability of investing in securities generally or in the Fund particularly, or the ability of the Underlying Index or any related indices or sub-indices to track the appropriate market performance, or as to the results to be obtained by the Trust, the Fund, the Fund's shareholders or any other person or entity from use of the Underlying Index or any data included therein. None of such parties have any liability for any errors, omissions, or interruptions in the Underlying Index or such data, and the Index Provider and CBOE do not guarantee the accuracy or the completeness of the Underlying Index or such data. Neither the Index Provider nor CBOE make any express or implied warranties, and expressly disclaim all warranties of merchantability or fitness for a particular purpose or use with respect to the Underlying Index or such data. Without limiting any of the foregoing, the Index Provider, Dow Jones, S&P, CBOE, their affiliates and third party licensors expressly disclaim any and all liability for any special, punitive, indirect, or consequential damages (including lost profits), even if notified of the possibility of such damages.

The only relationship of the Index Provider, CBOE, their affiliates or their third party licensors to AccuShares, the trustee of the Trust (the "Trustee"), the Trust or the Fund is the licensing of certain trademarks, trade names and service marks and of the Underlying Index, which is constructed, calculated and published by CBOE, and has been licensed by the Index Provider, without regard to AccuShares, the Trustee, the Trust or the Fund. Neither AccuShares, the Trustee, the Trust nor the Fund have any contractual relationship or other arrangement with CBOE with respect to the use of the Underlying Index and related intellectual property. Instead, the rights of AccuShares, the Trust and the Fund to utilize the Underlying Index and related intellectual property is derivative of the rights of the Index Provider under its agreement with CBOE. CBOE has no obligation to take the needs of AccuShares, the Trustee, the Trust, the Fund or the Fund's shareholders into consideration in determining, composing or calculating the Underlying Index.

Neither the Index Provider, CBOE, nor any of their respective affiliates or third party licensors is responsible for or has participated in the determination of the timing, price or quality of the shares issued by the Fund or in the determination or calculation of the equation by which the shares are to be converted into cash. Neither the Index Provider, CBOE, nor any of their respective affiliates or third party licensors shall have any obligation or liability, including, without limitation, to Fund investors, in connection with the administration, marketing or trading of the Fund.

The Underlying Index is a product of CBOE, which is licensed by the Index Provider or its affiliates to AccuShares in connection with the operation of the Fund. Standard & Poor's ® and S&P ® are registered trademarks of S&P; Dow Jones ® is a registered trademark of Dow Jones; CBOE ® , Chicago Board Options Exchange ® , CBOE Volatility Index ® and VIX ® are registered trademarks of CBOE; and these trademarks have been licensed for use by the Index Provider and sublicensed for certain purposes by AccuShares. AccuShares ™ is a trademark of AccuShares Holdings LLC.

Foreside Fund Services, LLC Marketing Agent

AccuShares investor Service Center 1-855-286-7866 info@accushares.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 45

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 106

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 52

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 111

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 77

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 45

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 83

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Tevogen Bio Achieves Nasdaq Compliance and Future Prospects

Updated Category News Views 107

Tevogen Bio Regains Compliance with Nasdaq Listing Standards Tevogen Bio Holdings Inc. (NASDAQ: TVGN), a clinical-stage company specializing in immunotherapy, recently made headlines with its announcement of regained compliance with Nasdaq's listing standards. This pivotal moment for Tevogen showcases its dedication to maintaining a strong presence in the biotech...

Continue Reading
aTyr Pharma Investors: Join the Class Action Opportunity

Updated Category News Views 270

Understanding Your Rights as a Shareholder of aTyr Pharma Investors in aTyr Pharma, Inc. (NASDAQ: ATYR) are currently faced with a significant opportunity as a class action lawsuit has been initiated. This legal action is directed towards addressing serious concerns regarding the company's disclosures and conduct during a specific timeframe when many shareholders acquired...

Continue Reading
Chinafy and Lianwei Unite for Enhanced Web Solutions

Updated Category News Views 260

Chinafy and Lianwei Unveil Strategic Collaboration In an exciting development, Chinafy, a renowned cross-border web optimization platform, has announced a strategic partnership with Lianwei, a reputable provider of security and compliance consulting services. This collaboration marks the beginning of a new chapter in ensuring efficient web performance and regulatory...

Continue Reading
Insights on Octopus AIM VCT 2 plc's Current Net Asset Value

Updated Category News Views 107

Understanding the Current Net Asset Value of Octopus AIM VCT 2 plc Octopus AIM VCT 2 plc is a venture capital trust that has recently disclosed some important financial metrics regarding its net asset value (NAV). Knowing the NAV is crucial for investors as it represents the value of the company's assets minus liabilities, particularly helpful for assessing the worth of...

Continue Reading
FTAI Aviation: Unpacking Market Sentiment and Trends

Updated Category News Views 195

Understanding the Current Market Sentiment of FTAI Aviation In the realm of investments, the behavior of high-capital investors, often referred to as "whales," provides insightful indicators of market trends. Recently, these investors have taken a notably bearish stance on FTAI Aviation. Upon analyzing the options trading history for FTAI Aviation, there have been a total...

Continue Reading